Solriamfetol

Long COVID-19

Duke UniversitySmall moleculePhase 2Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 89/ 100

Competitive context

31 Active assets in the Long COVID-19 cohort.

Asset / Sponsor	Phase	Rating
Immulina Tm University of Mississippi Medical Center	Phase 3	BB
Ivabradine Kanecia Obie Zimmerman	Phase 2	B
Sirolimus Icahn School of Medicine at Mount Sinai	Phase 3	B
Paxlovid Kanecia Obie Zimmerman	Phase 2	B
NORVIR Kanecia Obie Zimmerman	Phase 2	B

View all 31 →

Same molecule, other indications

Solriamfetol is also rated in:

hypersomniaActive

BB

Indicative · Phase 2

67 / 100

sleep disorderActive

B

Indicative · Phase 2

57 / 100

major depressive disorderActive

CCC

Indicative · Phase 3

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.